The use of PET in Parkinson's disease

Brain Cogn. 1995 Aug;28(3):297-310. doi: 10.1006/brcg.1995.1259.


Activation studies with positron emission tomography (PET) have provided an understanding of the pathophysiology of akinesia and tremor in Parkinson's disease (PD). [18F]6-fluoro-L-dopa (FD)-PET and dopamine receptor imaging by PET can assist in the differential diagnosis of various forms of parkinsonism. FED-PET is capable of detecting subclinical dopaminergic deficits. This allows not only the early or preclinical detection of PD but also the investigation of subclinical lesions of the substantia nigra in PD-related disorders. Longitudinal studies of PD and MPTP induced parkinsonism have provided new insight into the pathogenesis of PD.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / therapeutic use
  • Aging
  • Antiparkinson Agents / therapeutic use
  • Binding Sites
  • Brain / diagnostic imaging*
  • Brain / metabolism
  • Brain / physiopathology
  • Corpus Striatum / physiopathology
  • Diagnosis, Differential
  • Humans
  • Neurotransmitter Agents / physiology
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / drug therapy
  • Parkinson Disease / physiopathology*
  • Receptors, Dopamine D2 / physiology
  • Substantia Nigra / physiopathology*
  • Tomography, Emission-Computed*


  • Antiparkinson Agents
  • Neurotransmitter Agents
  • Receptors, Dopamine D2
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine